Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FT 538 (Primary) ; Avelumab; Cetuximab; Trastuzumab
  • Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Male breast cancer; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Fate Therapeutics

    • Most Recent Events

    • 19 Sep 2023 Status changed from active, no longer recruiting to discontinued.
    • 28 Apr 2023 Status changed from recruiting to active, no longer recruiting.
    • 03 Nov 2022 According to Fate Therapeutics media release, the Company will present initial clinical data from the first eight patients treated in the first three-dose escalation cohort (100 million cells per dose) of FT538 in combination with cetuximab (n=3), trastuzumab (n=2), and avelumab (n=3) at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top